Literature DB >> 7571352

Hemodialysis removal of acyclovir.

J B Leikin1, L Shicker, J Orlowski, A T Blair, K McAllister.   

Abstract

A 59-y-old with a history of chronic renal failure on hemodialysis was diagnosed with herpes zoster and begun on 800 mg acyclovir 5 times daily. Two days later the patient developed visual hallucinations, ataxia, confusion and memory loss along with focal myoclonus, nausea and vomiting. No fever, elevated WBC count or significant electrolyte imbalance was found. CT scan of the brain was unremarkable. The patient was then dialyzed for presumed acyclovir toxicity. Her acyclovir level was later found to have been 3.4 micrograms/ml (normal peak range 0.4-2 micrograms/ml) prior to dialysis. After 3 h of hemodialysis, her post-dialysis acyclovir level was 1.9 micrograms/ml. After a second course of hemodialysis the next day the patient's mental status improved, and she was discharged 5 d later. Due to its low volume of distribution (0.6 L/kg), low protein binding (about 15%) and water solubility, acyclovir is an example of the ideal drug that can be removed by hemodialysis. About 45% of the total body amount can be extracted through a 3-h course of hemodialysis with resultant improvement in symptoms.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7571352

Source DB:  PubMed          Journal:  Vet Hum Toxicol        ISSN: 0145-6296


  2 in total

Review 1.  Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.

Authors:  Michael A Veltri; Alicia M Neu; Barbara A Fivush; Rulan S Parekh; Susan L Furth
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

2.  Valacyclovir Neurotoxicity and Nephrotoxicity in an Elderly Patient Complicated by Hyponatremia.

Authors:  Takuya Murakami; Tetsu Akimoto; Mari Okada; Erika Hishida; Taro Sugase; Atsushi Miki; Marina Kohara; Hiromichi Yoshizawa; Takahiro Masuda; Takahisa Kobayashi; Osamu Saito; Shigeaki Muto; Daisuke Nagata
Journal:  Drug Target Insights       Date:  2018-06-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.